"Antiemetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to prevent NAUSEA or VOMITING.
| Descriptor ID |
D000932
|
| MeSH Number(s) |
D27.505.696.663.050.030 D27.505.954.427.095 D27.505.954.483.200
|
| Concept/Terms |
Antiemetics- Antiemetics
- Antiemetic Drugs
- Drugs, Antiemetic
- Anti-emetics
- Anti emetics
- Antiemetic Agents
- Agents, Antiemetic
Antiemetic Effect- Antiemetic Effect
- Effect, Antiemetic
- Anti-Emetic Effects
- Anti Emetic Effects
- Effects, Anti-Emetic
- Antiemetic Effects
- Effects, Antiemetic
- Anti-Emetic Effect
- Anti Emetic Effect
- Effect, Anti-Emetic
|
Below are MeSH descriptors whose meaning is more general than "Antiemetics".
Below are MeSH descriptors whose meaning is more specific than "Antiemetics".
This graph shows the total number of publications written about "Antiemetics" by people in this website by year, and whether "Antiemetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 5 | 0 | 5 |
| 1998 | 3 | 0 | 3 |
| 1999 | 2 | 1 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 4 | 1 | 5 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 8 | 2 | 10 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 5 | 1 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiemetics" by people in Profiles.
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
-
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
-
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2023 03 17; 28(3):208-213.
-
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
-
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
-
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
-
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275.
-
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.